COVID-19 Pandemic


Current status of authorisations for combating COVID-19

Applications  received by Swissmedic for the authorisation (or authorisation extension in the case of vaccines) for COVID-19 vaccines and therapeutic agents against COVID-19 and the current status of the authorisation procedures.

Empfehlung des Bundesrates: Bleiben Sie zu Hause, insbesondere, wenn Sie alt oder krank sind

Information on the current situation in Switzerland

Information for health professionnals, FAQs, recommendations for travellers.

 
Official information page
Covid-FAQ

FAQ on the COVID-19 vaccines

On this page you’ll find answers to frequently asked questions about mRNA vaccines.


All about the vaccines - briefly and concisely explained

Vaccines: Rapid solution for new diseases?

Swismedic - The way a vaccination works

How an mRNA vaccine works

How a vector vaccine works?

How a protein vaccine works

How is the safety of vaccines monitored?


Communication regarding COVID-19

05.07.2024

Reports of suspected adverse reactions to the COVID-19 vaccines in Switzerland

COVID-19 vaccinovigilance reports up to the end of June 2024

01.07.2024

Ordinance 3 on Measures to Combat the Coronavirus (COVID-19) ceases to apply as of 30 June 2024

As there will no longer be any legal basis for doing so, Swissmedic will cease granting exceptions with regard to the authorisation and importing of medicinal products for the treatment or prevention of COVID-19

18.12.2023

Application for COVID-19 vaccine Nuvaxovid against Omicron variant XBB.1.5 withdrawn

The manufacturer Novavax is no longer pursuing marketing authorisation for its COVID-19 vaccine in Switzerland

01.11.2023

Out-of-Stock – COVID-19 – Authorisations for the temporary import and distribution of human medicines – Update

Licences in accordance with art. 22 para. 3 of the COVID 19 Ordinance 3

28.09.2023

Swissmedic approves Moderna Switzerland GmbH coronavirus vaccine Spikevax XBB.1.5

Spikevax XBB.1.5 approved for persons aged 18 and over

22.09.2023

Swissmedic approves Pfizer coronavirus vaccine Comirnaty XBB.1.5

Comirnaty XBB.1.5 approved for persons aged 12 and over

30.08.2023

Authorisation application submitted for coronavirus vaccine Nuvaxovid XBB.1.5

Swissmedic examining application for vaccine against Omicron subvariant XBB.1.5

21.08.2023

Clinical trials on medicinal products - Pandemic by SARS-CoV-2

Recommendations Swissmedic / swissethics for the treatment of patients

19.07.2023

Pfizer AG submits authorisation application for coronavirus vaccine Comirnaty XBB.1.5

Swissmedic examining application for vaccine against Omicron subvariant XBB.1.5

13.07.2023

Moderna submits authorisation application for coronavirus vaccine Spikevax XBB.1.5

Swissmedic examining application for vaccine against Omicron subvariant XBB.1.5
https://www.swissmedic.ch/content/swissmedic/en/home/news/coronavirus-covid-19.html